Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 13Methotrexate 12Cytarabine 11Dexamethasone 10Vincristine 9Etoposide 7Radiotherapy 6Mercaptopurine 6Daunorubicin 6Asparaginase 6pegaspargase 5blinatumomab 5Dasatinib 5Prednisone 4Methylprednisolone 4Filgrastim 4Doxorubicin 4ruxolitinib 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Busulfan 3Antilymphocyte Serum 3venetoclax 2fludarabine phosphate 2fludarabine 2etoposide phosphate 2calaspargase pegol 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Homoharringtonine × Clear all
NCT06855810 2025-08-26

CCCG-TALL-2025

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
610 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡